Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+/HER2- Advanced Breast Cancer.

2 , 5 In contrast, in Cohort B, there was a numerical trend toward ESR1 mutations and shorter PFS. 5 These findings suggest that treatment with alpelisib plus fulvestrant may be the preferred option for patients with HR-positive, HER2-negative, PIK3CA -mutated advanced breast cancer when the presence of an ESR1 mutation is suspected.

also in 1,012 other papers